Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic plc (NYSE: MDT) shares have weakened more than 4% after the company reported weaker than expected fourth-quarter results. The company missed estimates with Q4 EPS and Q4 revenue, and the research company Needham downgraded Medtronic from buy to hold.

Should I buy Medtronic shares in June 2022?

NewCo is expected to operate successfully, leveraging Medtronic's (MDT) capabilities as a healthcare technology leader and DaVita's deep expertise as a comprehensive kidney care provider.

Medtronic's (MDT) New JV With DaVita to Expand Renal Care Line

Kraft Heinz

Some companies failed to join in on gains of as much as 3% for major indexes.

2 Blue Chip Stocks That Missed Thursday's Big Rally

Medtronic plc (NYSE:MDT ) Q4 2022 Earnings Conference Call May 26, 2022 8:00 AM ET Company Participants Ryan Weispfenning - Head of IR Geoff Martha - CEO Karen Parkhill - CFO Brad Lerman - SVP, General Counsel, Corporate Secretary Bob White - EVP and President of the Medical Surgical Portfolio Sean Salmon - EVP and President of the Cardiovascular Portfolio and former Head of the Diabetes Operating Unit Conference Call Participants Vijay Kumar - Evercore ISI Travis Steed - Bank of America Merrill Lynch Larry Biegelsen - Wells Fargo Shagun Singh - RBC Capital Markets Josh Jennings - Cowen Joanne Wuensch - Citi Pito Chickering - Deutsche Bank Ryan Weispfenning Good morning. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations.

Medtronic plc (MDT) CEO Geoff Martha on Q4 2022 Results - Earnings Call Transcript

On a positive note, Medtronic (MDT) registers organic growth in the Cardiovascular and Neuroscience segments.

Medtronic's (MDT) Q4 Earnings and Revenues Lag Estimates

DaVita

Medtronic plc (NYSE: MDT) and DaVita Inc (NYSE: DVA) intend to form a new, independent kidney care-focused medical device company (NewCo). NewCo will focus on developing a broad suite of novel kidney care products and solutions, including future home-based products.

Medtronic, DaVita To Jointly Form Kidney Health-Focused Company

Medtronic (MDT) delivered earnings and revenue surprises of -2.56% and 3.85%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Q4 Earnings and Revenues Lag Estimates

Medtronic Plc's (NYSE: MDT) Q4 FY22 sales of $8.09 billion decreased 1% Y/Y on a reported basis but increased 1% organically, missing the consensus of $8.42 billion. The company has forecasted Q4 organic revenue growth of approximately 5.5%.

Why Are Medtronic Shares Plunging Today?

The medical-device maker has had a stutter-step recovery from the impact of the Covid-19 pandemic.

Citing Supply-Chain Impact, Medtronic Misses Guidance

Shares of Medtronic PLC PLC, -0.31% dropped 3.2% in premarket trading Thursday, after the medical technology company missed fiscal fourth-quarter profit and sales expectations and provided a downbeat earnings outlook, citing pressure from inflation, supply chain constraints and COVID-19 controls in China. Net income rose to $1.49 billion, or $1.10 a share, from $1.36 billion, or $1.00 a share, in the year-ago period.

Medtronic stock falls after earnings miss and downbeat outlook, but dividend boosted

Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdowns DUBLIN , May 26, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2022, which ended April 29, 2022. Key Highlights FY22 revenue increased 5% reported and organic FY22 GAAP diluted EPS increased 40%; non-GAAP diluted EPS increased 26% FY22 cash flow from operations of $7.3 billion increased 18%; FY22 free cash flow of $6.0 billion increased 22% Quarterly dividend increased to $0.68, annual $2.72 from prior $2.52; 45th consecutive year of dividend increases Q4 revenue of $8.1 billion decreased 1% reported and increased 1% organic Q4 GAAP diluted EPS of $1.10 increased 10%; non-GAAP diluted EPS of $1.52 increased 2% Company issues FY23 guidance Fiscal year 2022 revenue of $31.686 billion increased 5% as reported and organic, which excludes the $75 million negative impact of foreign currency translation.

Medtronic reports full year and fourth quarter fiscal year 2022 financial results; announces 8% dividend increase

Companies join forces to accelerate kidney care device innovation and improve patient outcomes DUBLIN and DENVER, May 26, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT) and DaVita Inc. (NYSE:DVA) today announced the intent to form a new, independent kidney care-focused medical device company ("NewCo" or "the Company") to enhance the patient treatment experience and improve overall outcomes. By bringing together Medtronic's capabilities as a healthcare technology leader and DaVita's deep expertise as a comprehensive kidney care provider, NewCo will be uniquely positioned to advance the development of differentiated therapies for patients with kidney failure.

Medtronic and DaVita announce new kidney health technology company

Medtronic (NYSE: MDT) is scheduled to report its fiscal fourth-quarter results on Thursday, May 26.

Will Medtronic Stock See Higher Levels Following Its Q4 Results?

CVS Health

General Dynamics

American stocks are not doing well. On Friday, the S&P 500 moved close to a bear market and analysts believe that this will happen in the near term.

Best 3 defensive stocks to buy as the S&P nears a bear market

Ashland Global Hlds

Lowe's

Insperity

Ralph Lauren

After years of a low interest rate environment, which now is trending higher, many investors have turned to equities, not only for the growth potential but also for the solid and dependable dividends that help to provide an income stream.

5 Analyst Favorite Blue Chip Stocks to Buy With Dividend Hikes Likely This Week

Merck

These two leading companies have survived market downturns before.

2 Safe Stocks to Buy in a Bear Market

Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medtronic (MDT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

DUBLIN , May 19, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2022 on Thursday, May 26, 2022. A news release will be issued at approximately 5:45 a.m.

Medtronic to announce financial results for its fourth quarter and full fiscal year 2022

Looking at stock returns, Eli Lilly's 55% growth is much better than Medtronic's -16% change over the last twelve months.

Here's What Makes Medtronic Stock A Better Pick Over This Pharmaceuticals Company

AbbVie

Iron Mountain

Coca-Cola

Mondelez

T-Mobile US

UnitedHealth Group

Bear markets are an inevitable if particularly unpleasant part of the market cycle. But investors who hold the best stocks to buy for bear markets can mitigate at least some of the damage.

The 10 Best Stocks for a Bear Market

Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE DUBLIN and PARIS , May 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral™ Renal Denervation (RDN) system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials on May 17, 2022.

EuroPCR: Medtronic renal denervation system shows better blood pressure control with significantly more time in target range

Medtronic's (MDT) Onyx Frontier DES is utilized to treat patients with CAD.

Medtronic's (MDT) Onyx Frontier DES Receives FDA Approval

Investors are optimistic about Medtronic's (MDT) rising market share gains and ongoing business recovery.

Here's Why Investors Should Retain Medtronic (MDT) Stock

The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent DUBLIN , May 13, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier™ drug-eluting stent (DES). As the latest evolution in the Resolute DES family, Onyx Frontier DES leverages the same best-in-class stent platform as Resolute Onyx™ DES, with an enhanced delivery system1 designed to improve deliverability and increase acute performance2 in even the most challenging of cases.1 The Onyx Frontier DES is used for the treatment of patients with coronary artery disease (CAD), which is caused by plaque buildup on the inside of the coronary arteries.

Medtronic receives FDA approval for latest generation drug-eluting coronary stent system

Acquisition adds innovative bioabsorbable steroid-eluting sinus implants to ENT portfolio DUBLIN and MENLO PARK, Calif. , May 13, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Intersect ENT, expanding the company's comprehensive ear, nose, and throat (ENT) portfolio with innovative products used in sinus procedures to improve post-operative outcomes and to treat nasal polyps.

News for Medtronic Stock (MDT)